According to the Zhitong Finance App, Danno Pharmaceutical-B (06872) issued an announcement. After comprehensive consideration of the existing clinical data, unmet clinical needs, competitive pattern and commercial potential of the new drug candidate rifoquinone (TNP-2092), the company has selected the treatment of artificial joint infections (PJI) through intra-articular injection as the core priority development indication for rifaquinone.

As the Group's core pipeline, rifuquinone has many application prospects. The phase IIa proof-of-concept clinical trial of rifuquinone was administered through intra-articular injection to treat PJI. The first patient was enrolled in the multi-center phase IIb clinical trial. The trial aims to further evaluate the efficacy, safety, and pharmacokinetic characteristics of rifaquinone in treating PJI without debridement or revision surgery, and marks a critical stage in clinical development of this potentially disruptive new drug product.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.